William Fry has advised Innocoll Holdings, a specialty pharmaceutical and medical device company with late stage development programmes targeting areas of significant unmet medical need, in respect of its recent $40.1m placing. The placing, underwritten by Morgan Stanley and Piper Jaffray, was in respect of 5,725,000 shares at a price to the public of $7 per share. The underwriters also have an over-allotment option over an additional 858,750 shares, subject to certain closing conditions.
The William Fry team advising on the deal was led by David Carthy, who was assisted by Laura Dunne, Sonya Manzor, David Jones and Rachel Fox.
